<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To describe the effect of additional treatment with anti-TNF-alpha therapy in a case series of 13 patients with serious sight threatening <z:hpo ids='HP_0000554'>uveitis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: 13 patients with serious sight threatening <z:hpo ids='HP_0000554'>uveitis</z:hpo> were included, of whom six had <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease, five had idiopathic <z:hpo ids='HP_0012123'>posterior uveitis</z:hpo>, one had <z:e sem="disease" ids="C0036202" disease_type="Disease or Syndrome" abbrv="">sarcoidosis</z:e>, and one birdshot <z:e sem="disease" ids="C0008513" disease_type="Disease or Syndrome" abbrv="">retinochoroiditis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0003674'>Onset</z:hpo> and course of <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo>, inflammatory signs, and visual acuity were assessed </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were treated with 200 mg (approximately 3 mg/kg) infliximab infusion </plain></SENT>
<SENT sid="4" pm="."><plain>Repeat infusions were given based on clinical response </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Infliximab treatment resulted in an effective suppression of <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo> in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="6" pm="."><plain>In patients with non-<z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> <z:hpo ids='HP_0000554'>uveitis</z:hpo> visual acuity in six out of eight improved or was stable </plain></SENT>
<SENT sid="7" pm="."><plain>In patients with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet's disease</z:e> visual acuity in five out of six improved or was stable </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: Anti-TNF-alpha treatment may be of value in the treatment of <z:hpo ids='HP_0000554'>uveitis</z:hpo>, and in patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's disease, leading to suppression of <z:hpo ids='HP_0100533'>ocular inflammation</z:hpo>, <z:hpo ids='HP_0002633'>vasculitis</z:hpo>, and improvement of vision in the majority </plain></SENT>
<SENT sid="9" pm="."><plain>Based on these results a controlled masked study is warranted </plain></SENT>
</text></document>